NYSE: OGNOrganon & Co Stock
$10.04-0.03 (-0.3%)
Updated Jun 13, 2025
OGN Price
$10.04
Fair Value Price
N/A
Market Cap
$2.61B
52 Week Low
$8.01
52 Week High
$23.10
P/E
3.45x
P/B
4.82x
P/S
0.61x
PEG
0.27x
Dividend Yield
5.78%
Revenue
$6.29B
Earnings
$750.00M
Gross Margin
57.2%
Operating Margin
18.83%
Profit Margin
11.9%
Debt to Equity
23.27
Operating Cash Flow
$938M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OGN Overview
Organon & Co. offers prescription drugs in the U.S. and internationally. Its Women's Health portfolio includes contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. Its Biosimilars portfolio consists immunology products (Brenzys, Renflexis, and Hadlima), as well as oncology products (Ontruzant and Aybintio). The company also offers cholesterol-modifying cardiovascular products (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor). Organon & Co. was incorporated in 2020 and is headquartered in Jersey City, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OGN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
OGN
Ranked#15 of 18
Ranked#15 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $119.45 | A | |
| $157.10 | B | |
| $8.87 | B |
Be the first to know about important OGN news, forecast changes, insider trades & much more!
OGN News
Overview
Due Diligence Score
–
Industry Average (43)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OGN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OGN ($10.04) is trading below its intrinsic value of $29.05, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OGN is good value based on its earnings relative to its share price (3.45x), compared to the US market average (31.36x)
P/E vs Market Valuation
OGN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more OGN due diligence checks available for Premium users.
Valuation
OGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
3.45x
Industry
39.4x
Market
31.36x
OGN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
OGN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
OGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.82x
Industry
6.12x
OGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OGN price to earnings growth (PEG)
For valuing profitable companies with growth potential
OGN is good value based... subscribe to Premium to read more.
PEG Value Valuation
OGN's financial health
Profit margin
Revenue
$1.5B
Net Income
$87.0M
Profit Margin
5.8%
OGN's Earnings (EBIT) of $1.19B... subscribe to Premium to read more.
Interest Coverage Financials
OGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.2B
Liabilities
$12.6B
Debt to equity
23.27
OGN's short-term assets ($4.37B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OGN's long-term liabilities ($10.00B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$75.0M
Investing
-$172.0M
Financing
-$75.0M
OGN's operating cash flow ($938.00M)... subscribe to Premium to read more.
Debt Coverage Financials
OGN vs General Drug Manufacturer Stocks
Organon & Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.